KeyCorp Forecasts Strong Price Appreciation for ICU Medical (NASDAQ:ICUI) Stock

ICU Medical (NASDAQ:ICUI) had its price target boosted by equities researchers at KeyCorp from $164.00 to $182.00 in a research note issued on Tuesday, MarketBeat.com reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s target price suggests a potential upside of 15.60% from the stock’s previous close.

Several other equities research analysts also recently commented on ICUI. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 27th. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $172.00.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $157.44 on Tuesday. The company has a 50 day simple moving average of $142.83 and a two-hundred day simple moving average of $139.51. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $162.85. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of 85.10, a P/E/G ratio of 2.22 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts expect that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently bought and sold shares of ICUI. Hilton Head Capital Partners LLC bought a new position in ICU Medical during the 4th quarter valued at about $32,000. Covestor Ltd grew its stake in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 126 shares during the period. Strs Ohio grew its position in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. raised its stake in ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in ICU Medical during the 4th quarter valued at $120,000. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.